Extended therapy with [(177)Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer

PURPOSE: The currently used scheme for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC) consists of 4–6 cycles of 6.0–7.4 GBq [(177)Lu]Lu-PSMA-617 each. This standard treatment scheme has proved safe and effective resulting in objective response in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Mader, Nicolai, Nguyen Ngoc, Christina, Kirkgöze, Bilge, Baumgarten, Justus, Groener, Daniel, Klimek, Konrad, Happel, Christian, Tselis, Nikolaos, Chun, Felix K. H., Grünwald, Frank, Sabet, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119067/
https://www.ncbi.nlm.nih.gov/pubmed/36702927
http://dx.doi.org/10.1007/s00259-023-06119-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119067/
https://www.ncbi.nlm.nih.gov/pubmed/36702927
http://dx.doi.org/10.1007/s00259-023-06119-1

Ejemplares similares